EU committee rejects Vivus weight-loss drug

Published on NewsOK Modified: February 22, 2013 at 6:33 am •  Published: February 22, 2013
Advertisement
;

"We have worked diligently throughout Europe with key opinion leaders and regulatory and risk management experts to highlight the favorable safety and efficacy profile of Qsiva," he said, noting that a committee scientific advisory group gave the drug a positive recommendation.

Qsymia is the company's only marketed product. U.S. sales of the drug started slowly, something Vivus has attributed in part to high out-of-pocket costs for patients and limited insurance coverage.

But the company said in January that prescriptions for the weight loss pill surged in late November and December. Analysts say annual sales of Qsymia will eventually top $1 billion.

Vivus shares finished at $12.88 on Thursday. Its shares have rebounded from a 52-week low of $9.86 in mid-November. They are almost 60 percent below their high of $31.21 in mid-July.



Trending Now


AROUND THE WEB

  1. 1
    Native American tribe cancels Ted Nugent show, cites 'racist' views
  2. 2
    Body of fugitive billionaire in South Korean ferry case found
  3. 3
    KFOR: One of the dogs left behind 'because they needed to be bathed' has died
  4. 4
    KFOR: Class action lawsuit filed against Norman Regional Hospital
  5. 5
    KOCO: OHP concerned about rise in road rage incidents
+ show more